Low-dose D-penicillamine therapy in rheumatoid arthritis: A controlled, double-blind clinical trial

H. J. Williams; J. R. Ward; J. C. Reading; M. J. Egger; J. T. Grandone; C. O. Samuelson; D. E. Furst; J. M. Sullivan; M. A. Watson; M. Guttadauria; E. S. Cathcart; S. B. Kaplan; J. T. Halla; A. Weinstein; P. H. Plotz

Low-dose D-penicillamine therapy in rheumatoid arthritis: A controlled, double-blind clinical trial

H. J. Williams, J. R. Ward, J. C. Reading, M. J. Egger, J. T. Grandone, C. O. Samuelson, D. E. Furst, J. M. Sullivan, M. A. Watson, M. Guttadauria, E. S. Cathcart, S. B. Kaplan, J. T. Halla, A. Weinstein, P. H. Plotz

Research output: Contribution to journal › Article › peer-review

83 Scopus citations

Abstract

Two hundred twenty-five patients with active severe rheumatoid arthritis were admitted to a multiclinic, controlled, double-blind trial comparing the use of 500 mg d-penicillamine per day, 125 mg d-penicillamine per day, and placebo. One hundred seventy-one patients completed at least 30 weeks of therapy. The 500 mg D-penicillamine group demonstrated statistically significant improvement over the placebo group in grip strength, average circumference of swollen proximal interphalangeal joints, and patient assessment. While the trend was for greater improvement with the larger dose of D-penicillamine, there was no statistically significant difference among the 3 groups in duration of morning stiffness, walking time, physician's assessment, number of swollen joints, or scores for tender and swollen joints. The slight increase in efficacy of higher dose D-penicillamine was associated with increased toxicity.

Original language	English (US)
Pages (from-to)	581-592
Number of pages	12
Journal	Arthritis and Rheumatism
Volume	26
Issue number	5
State	Published - 1983
Externally published	Yes

ASJC Scopus subject areas

Immunology
Rheumatology

Cite this

Williams, H. J., Ward, J. R., Reading, J. C., Egger, M. J., Grandone, J. T., Samuelson, C. O., Furst, D. E., Sullivan, J. M., Watson, M. A., Guttadauria, M., Cathcart, E. S., Kaplan, S. B., Halla, J. T., Weinstein, A., & Plotz, P. H. (1983). Low-dose D-penicillamine therapy in rheumatoid arthritis: A controlled, double-blind clinical trial. Arthritis and Rheumatism, 26(5), 581-592.

@article{870d5a36b47e40998b870b6632d8f869,

title = "Low-dose D-penicillamine therapy in rheumatoid arthritis: A controlled, double-blind clinical trial",

abstract = "Two hundred twenty-five patients with active severe rheumatoid arthritis were admitted to a multiclinic, controlled, double-blind trial comparing the use of 500 mg d-penicillamine per day, 125 mg d-penicillamine per day, and placebo. One hundred seventy-one patients completed at least 30 weeks of therapy. The 500 mg D-penicillamine group demonstrated statistically significant improvement over the placebo group in grip strength, average circumference of swollen proximal interphalangeal joints, and patient assessment. While the trend was for greater improvement with the larger dose of D-penicillamine, there was no statistically significant difference among the 3 groups in duration of morning stiffness, walking time, physician's assessment, number of swollen joints, or scores for tender and swollen joints. The slight increase in efficacy of higher dose D-penicillamine was associated with increased toxicity.",

author = "Williams, {H. J.} and Ward, {J. R.} and Reading, {J. C.} and Egger, {M. J.} and Grandone, {J. T.} and Samuelson, {C. O.} and Furst, {D. E.} and Sullivan, {J. M.} and Watson, {M. A.} and M. Guttadauria and Cathcart, {E. S.} and Kaplan, {S. B.} and Halla, {J. T.} and A. Weinstein and Plotz, {P. H.}",

year = "1983",

language = "English (US)",

volume = "26",

pages = "581--592",

journal = "Arthritis and Rheumatism",

issn = "0004-3591",

publisher = "John Wiley and Sons Ltd",

number = "5",

}

TY - JOUR

T1 - Low-dose D-penicillamine therapy in rheumatoid arthritis

T2 - A controlled, double-blind clinical trial

AU - Williams, H. J.

AU - Ward, J. R.

AU - Reading, J. C.

AU - Egger, M. J.

AU - Grandone, J. T.

AU - Samuelson, C. O.

AU - Furst, D. E.

AU - Sullivan, J. M.

AU - Watson, M. A.

AU - Guttadauria, M.

AU - Cathcart, E. S.

AU - Kaplan, S. B.

AU - Halla, J. T.

AU - Weinstein, A.

AU - Plotz, P. H.

PY - 1983

Y1 - 1983

N2 - Two hundred twenty-five patients with active severe rheumatoid arthritis were admitted to a multiclinic, controlled, double-blind trial comparing the use of 500 mg d-penicillamine per day, 125 mg d-penicillamine per day, and placebo. One hundred seventy-one patients completed at least 30 weeks of therapy. The 500 mg D-penicillamine group demonstrated statistically significant improvement over the placebo group in grip strength, average circumference of swollen proximal interphalangeal joints, and patient assessment. While the trend was for greater improvement with the larger dose of D-penicillamine, there was no statistically significant difference among the 3 groups in duration of morning stiffness, walking time, physician's assessment, number of swollen joints, or scores for tender and swollen joints. The slight increase in efficacy of higher dose D-penicillamine was associated with increased toxicity.

AB - Two hundred twenty-five patients with active severe rheumatoid arthritis were admitted to a multiclinic, controlled, double-blind trial comparing the use of 500 mg d-penicillamine per day, 125 mg d-penicillamine per day, and placebo. One hundred seventy-one patients completed at least 30 weeks of therapy. The 500 mg D-penicillamine group demonstrated statistically significant improvement over the placebo group in grip strength, average circumference of swollen proximal interphalangeal joints, and patient assessment. While the trend was for greater improvement with the larger dose of D-penicillamine, there was no statistically significant difference among the 3 groups in duration of morning stiffness, walking time, physician's assessment, number of swollen joints, or scores for tender and swollen joints. The slight increase in efficacy of higher dose D-penicillamine was associated with increased toxicity.

UR - http://www.scopus.com/inward/record.url?scp=0020569256&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0020569256&partnerID=8YFLogxK

M3 - Article

C2 - 6342625

AN - SCOPUS:0020569256

SN - 0004-3591

VL - 26

SP - 581

EP - 592

JO - Arthritis and Rheumatism

JF - Arthritis and Rheumatism

IS - 5

ER -

Low-dose D-penicillamine therapy in rheumatoid arthritis: A controlled, double-blind clinical trial

Abstract

ASJC Scopus subject areas

Other files and links

Fingerprint

Cite this